Lineage Cell Therapeutics, Inc. Intangible Assets, Gross (Excluding Goodwill)
Lineage Cell Therapeutics, Inc. (LCTX) had Intangible Assets, Gross (Excluding Goodwill) of $66.14 million as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes
us-gaap:IntangibleAssetsGrossExcludingGoodwill · last filed 2024-11-14
- 2024-09-30: Intangible Assets, Gross (Excluding Goodwill) $66.14M.
- 2024-06-30: Intangible Assets, Gross (Excluding Goodwill) $66.14M.
- 2024-03-31: Intangible Assets, Gross (Excluding Goodwill) $66.14M.
- 2023-12-31: Intangible Assets, Gross (Excluding Goodwill) $66.14M.
| Period end | Intangible Assets, Gross (Excluding Goodwill) |
|---|---|
| 2024-09-30 | $66.14M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $66.14M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $66.14M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $66.14M 10-Q · filed 2024-11-14 |
| 2023-09-30 | $66.14M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $66.14M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $66.14M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $66.14M 10-K · filed 2024-03-07 |
| 2022-09-30 | $66.14M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $66.14M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $66.14M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $66.14M 10-K · filed 2023-03-09 |
| 2021-09-30 | $66.14M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $66.14M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $66.14M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $66.14M 10-K · filed 2022-03-10 |
| 2020-09-30 | $66.14M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $66.14M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $66.14M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $66.14M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |